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Abstract: We report the development of a combined confocal Raman 
spectroscopy (CRS) and optical coherence tomography (OCT) instrument 
(CRS-OCT) capable of measuring analytes in targeted biological tissues 
with sub-100-micron spatial resolution. The OCT subsystem was used to 
measure depth-resolved tissue morphology and guide the acquisition of 
chemically-specific Raman spectra. To demonstrate its utility, the 
instrument was used to accurately measure depth-resolved, physiologically-
relevant concentrations of Tenofovir, a microbicide drug used to prevent the 
sexual transmission of HIV, in ex vivo tissue samples. 
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1. Introduction 
To maximize their effectiveness, many therapeutic and prophylactic drugs must be delivered 
to specific tissue sites. For example, the target of vaginally-applied Tenofovir, a topical 
microbicide drug used to prevent the transmission of HIV, is primarily the stromal tissue 
underlying the superficial epithelium, which is where HIV-infectible cells reside [1]. The 
current gold-standard method used to measure Tenofovir concentrations in tissue is liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) [2]. Although it is highly sensitive, 
LC-MS/MS is destructive, expensive, and labor intensive. LC-MS/MS is also applied to 
homogenized tissue, and therefore cannot delineate the spatial concentration profiles of drugs, 
which drive both diffusion and delivery to specific tissue sites [1]. 
Optical imaging and spectroscopy methods offer an attractive, potentially noninvasive and 
less-expensive alternative for evaluating drug delivery to targeted tissues. For instance, 
optical coherence tomography (OCT) can measure depth-resolved tissue morphology up to 
one millimeter below the tissue surface [3,4] depending upon the type of tissue and its 
associated optical properties. Chemically-sensitive optical methods, such as Raman 
spectroscopy (RS) [5–11], can measure spatiotemporal distributions of analytes with up to 
micron-level spatial resolution when utilizing confocal detection [12]. In fact, confocal 
Raman spectroscopy has been recently applied, using commercially-available 
instrumentation, to detect Tenofovir in tissue samples ex vivo [13]. Combining confocal RS 
(CRS) with OCT in a single instrument could provide an accurate method to evaluate drug 
delivery to specific tissue sites or analyze the morphological and chemical properties of 
potentially pathologic tissues. 
A number of groups have previously developed combined RS and OCT instruments to 
characterize biological tissue. The first RS-OCT device combined a time-domain OCT system 
with a near-infrared Raman spectrometer to guide acquisition of Raman spectra from a 
localized malignancy in breast tissue [14]. Other RS-OCT instruments have varied in 
technical detail and application: a combined instrument that utilized spectral-domain OCT 
was developed for retinal imaging and spectroscopy [15]; a combined Raman and spectral-
domain OCT system was built using a single spectrometer with a common detection path and 
was used to sequentially acquire Raman and OCT data from rodent calvaria and retina and 
human skin [16]; a clinical instrument with a hand-held probe was developed to characterize 
cancerous skin lesions [17]; and a depth-sensitive Raman spectrometer was combined with 
OCT to analyze the epithelial and stromal layers of goat tissue [18]. 
Although the depth-sensitive instrument described above was used to acquire distinct 
Raman spectra from epithelial and stromal tissues [18], none of the previously-reported RS-
OCT instruments have been capable of measuring analytes on the sub-200-micron scale. High 
spatial resolution is desirable to accurately translate concentration gradients into fundamental 
molecular transport parameters such as diffusion coefficients. Here, we report the 
development of a combined CRS-OCT instrument capable of measuring co-localized 
morphological and chemical information with sub-100-micron resolution. This performance 
was achieved by independently adjusting the effective illumination numerical aperture (NA) 
of each subsystem as discussed in section 2.1. The axial resolution of the Raman subsystem 
was also measured as a function of sampling depth in two-layer, biological-tissue phantoms 
as described in section 2.3. As expected, the resolution degraded with increasing sampling 
depth, but remained better than 100 µm over the entire practical depth range. Finally, the 
utility of the instrument was demonstrated by combining co-localized CRS and OCT data to 
accurately measure depth-resolved, physiologically-relevant concentrations of Tenofovir in 
epithelial and targeted stromal layers of intact, ex vivo tissue samples. 
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2. Materials and methods 
2.1 Instrumentation 
Cross-sectional OCT images and co-localized Raman spectra were acquired with the 
instrument depicted in Fig. 1. The OCT subsystem consists of a fiber-based Michelson 
interferometer. Light from a superluminescent diode (SLD-371-HP3, Superlum, Moscow, 
Russia) is passed through a Faraday isolator (AC Photonics, Inc., Santa Clara, CA) and split 
into reference and sample arms with a 50:50 fiber coupler. A galvanometer mirror and 4F lens 
system scan the beam in the sample arm across the back aperture of a long working distance 
objective lens (HCX PL Fluotar L50X/0.55, Leica Microsystems Inc., Buffalo Grove, IL). 
The interference signal generated by combining the light returned by the sample with that 
returned by the reference arm is dispersed with a custom-built spectrometer onto a line scan 
camera (AViiVA UM2, e2v Inc., Milpitas, CA) achieveing a spectral resolution of 0.07 nm 
over the 810 – 860 nm spectral range. Polarization controllers in the source, sample, and 
detection arms are used to optimize the splitting ratio at the fiber coupler as well as the 
detected interferometric signal. 
The RS subsystem utilizes a laser diode (LD785-SH300, Thorlabs Inc., Newton, NJ) for 
excitation. The output from the laser is circularized with a cylindrical and spherical lens set. 
The light is then filtered with shortpass (FES0800, Thorlabs Inc., Newton, NJ) and bandpass 
(LD01-785/10-12.5, Semrock Inc., Rochester, NY) filters and focused onto the sample with 
the objective lens described above. This configuration delivers about 30 mW of power to the 
sample plane, which is approximately equal to the maximum permissible continuous exposure 
limit set by the American National Standards Institute for skin illuminated with 785-nm light 
[19]. A dichroic beamsplitter (LPD01-785RS-25, Semrock Inc., Rochester, NY) and a notch 
filter (NF03-785E-25, Semrock Inc., Rochester, NY) in the collection path reject the 
elastically scattered light and an achromatic tube lens (f = 40 mm) focuses the Stokes-shifted, 
Raman scattered light into a 100-µm-core-diameter, multimode optical fiber, which acts as a 
confocal pinhole. The fiber delivers the light to a spectrometer (BIGBLOCK, Wasatch 
Photonics Inc., Durham, NC) where it is dispersed onto a 1340 × 400 pixel array, back-
illuminated, deep-depletion, charge coupled device camera (PIX400BR-SF-Q-F-BB-A-US-D, 
Princeton Instruments, Trenton, NJ). A flip mirror is used to switch between the OCT and 
Raman modes of operation and a motorized translation stage (Newport Corp., Irvine, CA) is 
used to accurately position the sample. The subsystems were coaligned with a 1951 USAF 
resolution target, which provided high spatial contrast in both Raman and OCT data. 
One of the benefits of OCT relative to other imaging modalities is that the axial and lateral 
resolutions are decoupled; the axial resolution is determined by the coherence length of the 
source while the lateral resolution depends upon the size of the focused beam waist [20]. The 
depth of focus, however, remains linked to the lateral resolution of the instrument. In 
conventional OCT, lateral resolution is often sacrificed to achieve a larger depth of focus by 
using a low NA objective lens. Conversely, confocal Raman microscopes typically utilize 
high NA objectives in order to acquire depth-resolved spectra with high spatial resolution. To 
satisfy these conflicting design parameters (i.e., a low NA objective for OCT imaging and a 
high NA objective for confocal Raman measurements), the OCT illumination beam diameter 
is reduced to approximately 0.25 mm in order to underfill the back aperture of the objective 
lens (NA = 0.55). With this approach, the effective NA of the OCT illumination beam was 
approximately 0.03 while the NA of the Raman illumination remained 0.55. 
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Fig. 1. Diagram of the instrument used to acquire cross-sectional OCT images and co-localized 
Raman spectra through a common objective lens. Abbreviations: SLD, superluminescent 
diode; FI, faraday isolator; FC, fiber coupler; REF, reference arm; PC, polarization controller; 
GM, galvanometer mirror; 4F, 4F lens system; spec1, spectrometer #1; LD, laser diode; BSO, 
beam shaping optics; BP, bandpass filter; DBS, dichroic beamsplitter; NF, notch filter; MMF, 
multimode fiber; spec2, spectrometer #2; FM, flip mirror; OBJ, objective lens; MTS, 
motorized translation stage. 
Detailed instrument properties are listed in Table 1. For the OCT portion of the 
instrument, the signal-to-noise ratio (SNR) was calculated as 
 ( )1020 lSNR og / NDM NE E= × +    (1) 
where ME  is the maximum peak height of an axial scan (i.e., the magnitude of the Fourier-
transformed spectrum) acquired from a mirror with an exposure time of 100 µs, NE  is the 
standard deviation of the noise in the axial scan, and ND  is the optical density of a neutral 
density filter placed in the sample arm to prevent saturation of the detector. The axial 
resolution was determined by measuring the full-width at half maximum (FWHM) of the 
mirror peak in the axial scan and the lateral resolution and field of view were established by 
imaging a 1951 USAF resolution target. The imaging depth was quantified by recording the 
falloff in ME  as the mirror was translated in the sample arm. The SNR of the CRS subsystem 
was characterized by acquiring a spectrum of a silicon wafer with an exposure time of 1 
second and dividing the height of the peak near 520 cm−1 by the standard deviation of the 
noise. The resolution of the CRS subsystem was calculated as the FWHM of the signal 
acquired from the silicon wafer as it was translated through the focal volume. Finally, the 
spectral resolutions of both the OCT and Raman spectrometers were quantified by measuring 
the FWHMs of the spectral lines emitted from a mercury-argon gas-discharge lamp. 
Note that the axial resolution (i.e., round-trip coherence length, cl ) of the OCT subsystem 
is about 10% larger than the theoretical prediction for a Gaussian source with a center 
wavelength ( 0) of 830 nm and bandwidth (Δ ) of 45 nm 
2
0[ (2 ln(2) / ) (λ / Δλ) 7µm]cl π= × =  [21]. This difference is attributed to incomplete 
dispersion compensation between the sample and reference arms as well as the non-Gaussian 
spectral shape of the source. 
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Table 1. Detailed instrument properties 
              OCT              CRS 
Illumination power 3.0 mW at sample plane 30.0 mW at sample plane 
Illumination wavelength 0 = 830 nm, Δ  = 45 nm 0 = 785 nm, Δ  = 0.5 nm 
SNR 94 dB 36 dB 
Axial resolution (in air) 8 µm 19 µm 
Lateral resolution (in air) 40 µm 3 µm 
Spectral resolution 0.07 nm 3.3 cm−1 
Spectral range 810 – 860 nm 150 – 1950 cm−1 
OCT imaging depth 1.6 mm (−3 dB falloff) - 
OCT field of view 900 µm - 
A description of the procedures used to measure these properties can be found in section 2.1. 
2.2 Data processing 
The signal recorded by the OCT spectrometer, ( )I k , is given by 
 ( )( ) ( ) ( ) 2 ( ) ( ) cos 2Δ ,S R S RI k I k I k I k I k zk= + + ×  (2) 
where ( )SI k  and ( )RI k  are the intensities of the light returned from the sample and reference 
arms at absolute wavenumber k, respectively; and Δz  is the difference in optical path length 
between the sample and reference arms. Prior to acquiring OCT images, a pair of shutters was 
used to sequentially record ( )SI k  and ( )RI k  while blocking the light from the other arm of 
the instrument. These measurements were subracted from all subsequent ones in order to 
isolate the interference term. Next, the interference spectrum was remapped onto a linear 
wavenumber axis and a phase correction was applied to compensate for any dispersion 
imbalance between the sample and reference arms [22,23]. Finally, the processed interference 
spectrum was Fourier transformed to determine the depth-resolved reflectivity of the sample. 
A number of routines were used to process Raman spectra. Background signal, including 
laser-induced fluorescence from the system optics, was removed by subtracing a separately-
acquired background spectrum. The Raman shift axis was calibrated with polystyrene to 
correct for spectral instabilities in the laser diode and fluorescence lineshapes were modeled 
and removed with an iterative polynomial fitting routine [24,25]. Impulsive noise (e.g., noise 
due to high-energy cosmic rays) was removed by (1) acquiring multiple frames per 
acquisition; (2) calculating the median absolute deviation among these frames on a pixel-by-
pixel basis; and (3) replacing outliers with the median value at that pixel. Finally, the spectra 
were smoothed with a Savitzky-Golay filter [26] over a 5 cm−1 window, which was chosen to 
approximately match the resolution of the spectrometer. Although Raman data were acquired 
over the full spectral range of the instrument (150 – 1950 cm−1), the processed spectra were 
cropped for display purposes in Figs. 2, 4, and 6 below. All data acquisition and processing 
routines were executed in LabVIEW (version 2012, National Instruments, Austin, TX) or 
MATLAB® (version 8.1, MathWorks, Natick, MA). 
2.3 Determination of axial resolution in biological tissue 
The resolutions listed in Table 1 were measured in non-scattering samples. In turbid media 
(e.g., biological tissue) resolution degrades as a function of sampling depth because scattering 
both attenuates the ballistic signal (the primary component measured by both confocal 
microscopy and OCT) and obscures it with a diffuse background. Spherical aberration due to 
the refractive index mismatch at sample surface also degrades resolution [27]. 
In order to characterize the effects of scattering and spherical aberration on axial 
resolution, two-layer tissue phantoms were constructed and the edge response of the CRS 
subsystem was measured across the boundary between the layers as a function of the top-
layer thickness. A diagram depicting the phantoms, including the optical properties of each 
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layer, is presented in Fig. 2(d). The top layer was a mixture of Intralipid (Liposyn II, Hospira, 
Lake Forest, Illinois) and India ink while the bottom layer was a mixture of 
polydimethylsiloxane (PDMS), polystyrene microspheres (PM), and India ink. To fabricate 
the bottom layer, PM (0.25-µm radius, Duke Scientific, Microgenics Corporation, Fremont, 
CA) were stirred into a PDMS base agent (Dow Corning, Midland, MI) and mixed with a 
curing agent at a 10:1 base-to-curing-agent ratio. The solution was vortexed and sonicated to 
create a homogenous mixture and placed in a vacuum chamber for 45 minutes to remove air 
bubbles. The mixture was cured at room temperature for 24 hours. 
The scattering and absorption coefficients of the phantom constituents were determined as 
a function of concentration by measuring the on-axis, narrow solid-angle transmission of each 
component [Fig. 2(a)-2(c)] in the single-scattering regime as described previously [8]. 
Reduced scattering coefficients were determined based upon scattering anisotropy values 
reported in the literature or calculated from Mie theory [28]. All optical properies were 
measured at the illumination wavelength of the CRS subsystem (785 nm). After determining 
the relationship between the concentration of each constituent and the resulting optical 
properties of the mixture, the final concentrations in the tissue phantoms were chosen to 
match the average optical properties of esophageal tissue [29–33]. We chose to model 
esophageal tissue because the optical properties of vaginal tissue have not been well 
established in the literature. Both of these tissues also have non-keratinized stratified 
squamous epithelia suggesting that the optical properties of esophageal tissue are a reasonable 
representation of those associated with vaginal tissue. 
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Fig. 2. Procedure used to measure the axial resolution of the CRS subsystem as a function of 
sampling depth in tissue phantoms. (a)-(c) Scattering or absorption coefficient of phantom 
constituents versus concentration, C, along with least-squares linear fits. Error bars represent 
the standard deviation of each measurement. (d) Diagram depicting the optical properties 
(determined with 785-nm illumination) and physical dimensions of the two-layer tissue 
phantoms. The top layer was a mixture of Intralipid and India ink while the bottom layer was a 
mixture of PM, PDMS, and India ink. (e) Representative, cross-sectional OCT image of a 
tissue phantom with a top-layer thickness of 140 µm. (f) Representative Raman spectrum of a 
tissue phantom acquired near the boundary between the layers along with the corresponding 
least-squares fit showing the underlying spectral components (offset for clarity). (g) 
Normalized signal intensity of the bottom-layer spectrum versus focal position (z) for varying 
top-layer thicknesses, d. Each data set was fit with a Gaussian cumulative distribution function 
(black lines). 
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Prior to measuring each edge response, the thickness of the top layer was measured with 
the OCT subsystem [Fig. 2(e)]. Cross-sectional OCT images were also used to verify that the 
optical properties of the phantoms were homogeneous and that the layer thicknesses were 
constant over the entire measurement area. Next, Raman spectra were acquired as the focal 
position was adjusted across the boundary between the layers. The normalized signal from the 
bottom layer (PM, PDMS, and India ink mixture) was determined by least-squares fitting and 
is plotted in Fig. 2(g). This subfigure shows that the edge response broadens as the sampling 
depth increases. Finally, each edge response was fit with a Gaussian cumulative distribution 
function, 




 − = +  
  
 (3) 
where erf is the error function, z is the focal position or sampling depth, d is the thickness of 
the top layer, and σ  is the standard deviation of the underlying Gaussian function. The 
relationship between sampling depth and axial resolution, defined as the full-width at half 
maximum ( )[FWHM 2 2ln 2 ]σ= , is shown in Fig. 3(b). 
Because of the refractive index mismatch at the sample surface as well as light attenuation 
within the sample, there is not a one-to-one correspondence between axial translation of the 
motorized stage and the resulting change in the sampling depth of the CRS measurements 
[27]. In order to determine the relationship between the sampling depth, z, and the height of 
the motorized translation stage, stagez , the boundary in each measured CRS edge response 
(defined as the point where the bottom-layer spectral intensity reached 50% of the maximum 
value) was compared to the known thickness of the top layer of the phantom. The relationship 
between z and stagez  is displayed in Fig. 3(a). This relationship was used to calibrate the depth 
axis displayed in Fig. 2(g) and all subsequent figures. It should be noted that both the 
spherical aberration induced by the sample and the lack of one-to-one correspondence 
between z and stagez  could be mitigated by utilizing a water immersion objective that reduces 
the refractive index mismatch at the tissue surface. 
 
Fig. 3. (a) Relationship between the height of the motorized translation stage, stagez , and the 
CRS focal position or sampling depth, z. (b) Relationship between the axial resolution 
(FWHM) of CRS measurements and z. Least-squares fits suggest that both relationships are 
approximately linear over this range. 
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2.4 Porcine tissue samples 
Fresh porcine vaginal tissue obtained from a local abattoir were used for all biological tissue 
measurements. First, serial dilutions of Tenofovir in homogenized tissue samples were 
prepared to evaluate the sensitivity of the Raman spectrometer and build a concentration 
prediction model. The tissue was placed in a small volume of isotonic Ringer’s solution 
(Hospira Inc., Lake Forest, IL), homogenized with an Omni General Laboratory 
Homogenizer (Omni International, Kennesaw, GA), and then stored for 24 hours in Ringer’s 
solutions containing different concentrations of Tenofovir. Eleven total dilutions of Tenofovir 
in homogenized tissue were prepared with nominal mass fractions ranging from 0 to 0.0064 
(i.e., 0 to 0.64% w/w or 0 to 6.4 mg/mL) corresponding to the predicted range of 
concentrations delivered to the vagina by a standard-formulation gel loaded with 1% 
Tenofovir [1]. Each sample was separated into two homogenates: one analyzed with our 
CRS-OCT instrument and the other stored at −80°C and subsequently measured with gold-
standard LC-MS/MS to determine the true concentration of Tenofovir. A Raman spectrum of 
pure Tenofovir was also constructed by measuring a sample of 2% w/w Tenofovir in Ringer’s 
solution and subtracting a separately-acquired spectrum of the Ringer’s solution alone. 
The tissue samples measured with LC-MS/MS were diluted with water and mixed with 
isotopically-labeled Tenofovir (Tenofovir-IS) as an internal standard. An analytical column 
(XBridge C18, 2.1 × 20 mm, 5 μm, Waters Corp., Milford, MA) was used to retain analytes, 
which were then eluted under gradient conditions. Concentration measurements were 
acquired with a triple quadrupole mass spectrometer (Agilent 6410, Agilent Technologies, 
Inc., Santa Clara, CA) using electrospray ionization and positive ion m/z transitions of 
288/176 (Tenofovir) and 293/181 (Tenofovir-IS). 
The Raman spectrum acquired from each homogenized sample was normalized to the 
spectral contribution from the tissue alone, which was determined by least-squares fitting 
with separately-acquired spectra of tissue and of pure Tenofovir. Next, the area under the 
peak near 730 cm−1 (adenine ring breathing mode) [13] was calculated to predict the 
concentration of Tenofovir in the sample. A leave-one-out cross-validation approach based 
upon linear regressions of the LC-MS/MS data on the Raman-derived peak areas was used to 
generate the predictions. Figure 4 presents representative Raman spectra of porcine vaginal 
tissue, pure Tenofovir, and tissue homogenized with 0.64% w/w Tenofovir. 
Following the experiments on homogenized samples, data were acquired ex vivo from 
intact porcine vaginal tissue. A gel layer loaded with either 0% (control) or 1% Tenofovir was 
placed over the tissue and the entire sample was placed in a Transwell insert (Corning, Inc., 
Corning, NY) as described previously [13]. The samples were incubated for 5, 60, or 120 
minutes allowing Tenofovir to diffuse out of the gel and into the underlying tissue. At the end 
of the incubation period, the gel layer was removed, the tissue surface was cleaned with a 
sterile wipe, and the intact tissue was then immediately measured with the CRS-OCT system. 
The Raman-based prediction model developed with the homogenized samples was applied to 
estimate the concentration of Tenofovir in each intact tissue sample as a function of depth. 
Measurements were acquired up to the maximum practical penetration depth of 300 µm 
below the surface, which is approximately equal to the transport length or reduced mean free 
path of near-infrared light in the tissue. 
3. Results and discussion 
The cross-validated, Raman-based predictions of Tenofovir concentration in homogenized 
porcine vaginal tissue versus the gold-standard measurements acquired with LC-MS/MS are 
displayed in Fig. 5(a). The prediction accuracy was quantified by calculating the root mean 
squared error of cross-validation (RMSECV). Given a 10-minute integration time, the 
RMSECV was 0.03% w/w, which is also approximately equal to the minimum detectable 
concentration. More advanced chemometric methods, including partial least squares [34] and 
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hybrid-linear analysis [35], provided modest improvements (RMSECV = 0.02% w/w for 
both); further improvements in prediction accuracy could potentially be achieved with a 
calibration set that spans a larger range of the spectroscopic variability observed in biological 
tissue. For comparison, a recently-developed pharmacokinetic model of drug delivery 
indicates that the concentration of Tenofovir delivered to the epithelium and superficial 
stroma by a standard-formulation gel ranges between approximately 0.05 and 0.5% w/w for 
up to 8 hours after application [1]. This suggests that our instrument is sensitive to 
physiologically-relevant concentrations of Tenofovir in tissue. The relationship between 
prediction accuracy and integration time is presented in Fig. 5(b). A power-law fit reveals that 
the RMSECV is proportional to the inverse square root of integration time, as expected for 
shot-noise limited detection and linear prediction models [36]. 
 
Fig. 4. Representative Raman spectra of porcine vaginal tissue, pure tenofovir (TFV), and 
tissue homogenized with 0.64% w/w TFV (offset for clarity). The vertical bar highlights the 
spectral location of the adenine ring breathing mode near 730 cm−1. 
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Fig. 5. (a) Cross-validated, Raman-based predictions of Tenofovir concentration in 
homogenized, porcine vaginal tissue versus gold-standard measurements acquired with LC-
MS/MS. The root mean squared error of cross-validation (RMSECV) was 0.03% w/w for an 
integration time of 10 minutes per sample. (b) RMSECV versus total integration time in 
minutes (t) per sample. The solid lines represent a power-law fit and the 95% confidence 
interval of the fit. 
A representative OCT image of intact porcine vaginal tissue (prior to topical application 
of Tenofovir gel) along with depth-resolved Raman spectra acquired from the same location 
are presented in Fig. 6. Figure 6(a) shows the surface of the epithelial layer and also the 
boundary between the epithelial and stromal layers approximately 110 µm beneath the tissue 
surface. Spectroscopic differences due to variation in the biochemical properties (e.g., 
collagen content) of these layers are highlighted in Fig. 6(b). A comprehensive review of the 
biochemical and spectroscopic differences between epithelial and stromal layers can be found 
elsewhere [37,38]. 
 
Fig. 6. (a) Representative cross-sectional OCT image of intact, ex vivo porcine vaginal tissue. 
The arrow highlights the thickness of the superficial epithelium. The colorbar shows the axial 
locations where Raman spectra were acquired. (b) Co-localized, depth-resolved Raman spectra 
acquired from the same tissue sample (offset for clarity). Spectroscopic differences due to 
natural biochemical variation (e.g., collagen content) in the epithelium versus the stroma are 
highlighted by the pale-colored columns. The highlighted spectral regions include 
hydroxyproline and proline bands (800 – 1000 cm−1) and the amide III protein band (1200 – 
1400 cm−1). Note that the Raman data were cropped to the 800 – 1800 cm−1 spectral range for 
display purposes only; the full spectral range was retained for quantitative analyses. 
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Concentration profiles of Tenofovir in intact porcine vaginal tissue, derived from depth-
resolved Raman spectra acquired after topical application of the drug, are displayed in Fig. 7. 
The integration time for each data point was 2.5 minutes, which provided a concentration 
prediction uncertainty and limit of detection of about 0.05% w/w [see Fig. 5(b)]. The average 
depth of the interface between the epithelium and stroma was also measured with the OCT 
subsystem. The combined CRS and OCT data quantify the concentration of Tenofovir 
delivered to the superficial epithelium versus the targeted stromal layer. The figure also 
shows that the overall concentration gradient is initially flat, becomes steep at an intermediate 
time of t = 60 minutes, and then levels at t = 120 minutes as drug equilibrates across the 
layers due to depletion of drug from the overlying gel layer. Future work will focus on 
converting these concentration profiles into fundamental molecular transport parameters such 
as diffusion and partition coefficients. 
 
Fig. 7. Depth-resolved concentrations of Tenofovir in tissue. A standard-formulation gel 
loaded with 0% (control) or 1% Tenofovir was applied to the tissue surface in a Transwell 
assay and the concentration of the drug in the tissue was measured at 5, 60, or 120 minutes 
(min) post-application. Error bars and the limit of detection (LOD), both defined as the 
RMSECV calculated with homogenized tissue samples (Fig. 5), are also displayed. Co-
localized OCT images were acquired and used to determine the average depth of the interface 
between the epithelium and stroma. 
4. Conclusion 
This study presents a combined CRS-OCT instrument capable of acquiring cross-sectional 
OCT images and co-localized, chemically-specific Raman spectra with sub-100-micron 
spatial resolution. The instrument uses skin-safe light levels and was utilized to accurately 
measure depth-resolved, physiologically-relevant concentrations of Tenofovir, a microbicide 
drug used to prevent the sexual transmission of HIV, in ex vivo tissue samples. These results 
highlight the unique capacity of high-resolution CRS-OCT to evaluate analytes in targeted 
biological tissues. Further analysis of depth-resolved concentration profiles acquired with 
CRS-OCT could also lead to fundamental knowledge about the diffusion of drugs into and 
through distinguishable tissue layers, and the partitioning of drugs at interfaces between both 
the drug carrier and the tissue surface and various tissue layers [1,13]. Future applications of 
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this instrument can therefore contribute to anti-HIV microbicide science and development, 
and to the analysis of drug delivery to tissue more generally. 
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